ClinicalTrials.gg
CompletedNCT04550325Updated Jan 5, 2021

Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19

A Phase 1/2 interventional study of Kamada Anti-SARS-CoV-2 in Covid19 and Pneumonia, Viral, sponsored by Kamada, Ltd.. Completed at 4 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Kamada, Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies in COVID-19 with a site in Israel — 4 open to participants now, 7 under way, 3 of them phase 3. COVID-19 · Israel.

Enrollment
51st of 61
12 · median 56
Started
2020
with 45 others
Phase 1/2
8 of 91
none open now
Registered
24th of 91
by date

Among the 91 studies in COVID-19 with a site in Israel, this one is the 51st largest by enrollment of the 61 interventional ones that give a count, is one of 46 that started in 2020, is one of 8 in phase 1/2, and was the 24th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 91 studies in COVID-19 with a site in Israel are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in COVID-19 with a site in Israel, or all of them as a file.
02

Study summary

Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia

03

Conditions studied

  • Covid19
  • Pneumonia, Viral
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Laboratory confirmed SARS-CoV-2 infection by nasopharyngeal swab Real time polymerase chain reaction (RT-PCR)
  3. Hospitalized for COVID-19 pneumonia
  4. Dosing should be within 10 days of symptom start
  5. Able and willing to sign form

Exclusion criteria

Exclusion Criteria:

  1. History of to plasma products and/or severe Immunoglobulin A deficiency (\< 7 mg/dL)
  2. Requirement of high flow oxygen devices, or non-invasive ventilation or mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) at screening
  3. Cardiovascular instability
  4. History of thrombo-embolic events
  5. Acute renal failure or creatinine >2 mg/dL or estimated estimated (eGFR) \<30 mL/min
  6. History of lung transplantation
  7. Major surgery (abdominal and chest) within the last 4 weeks
  8. Severe chronic background disease, per investigator's judgement for example, Cirrhosis grade C, Dialysis, cardiac insufficiency ( III), pulmonary disease (\<50 percent of predicted) etc.
  9. Pregnancy or lactation
  10. Treatment with plasma units or immunoglobulin preparations within the last 4 weeks
  11. Participation in another pharmaceutical interventional clinical study within 4 weeks from screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Immune gamma globulin (IgG)

    Single dose of 4g Immune gamma globulin (IgG) preparation Kamada Anti-SARS-CoV-2 given as an intravenous infusion

    Biological: Kamada Anti-SARS-CoV-2

Interventions

  • BiologicalKamada Anti-SARS-CoV-2

    Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods

06

What researchers measure

Primary outcomes

  1. Adverse events, serious adverse events, and deaths

    Record adverse events, serious adverse events, and deaths

    Time frame: 14 days

  2. Adverse events, serious adverse events, and deaths

    Record adverse events, serious adverse events, and deaths

    Time frame: 28 days

Secondary outcomes

  1. AUC0-7 of Anti SARS CoV-2 antibodies

    Measurement of the area under the curve of anti SARS CoV-2 immunoglobulin

    Time frame: 7 days

  2. Neutralization activity

    Evaluate virus neutralization activity of patient's plasma

    Time frame: 7 days

Other outcomes

  1. Duration of Hospitalization

    Time patient spent in hospital

    Time frame: 84 days

  2. Clinical status on the 6 point ordinate scale

    Score on the 6 point ordinate scale

    Time frame: 84 days

07

Study locations

4 sites
  • Wolfson Medical Center
    Holon, 5822012, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Sheba Medical Center Hospital- Tel Hashomer
    Ramat Gan, 52621, Israel
  • Kaplan Medical Center
    Reẖovot, 7661041, Israel
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Nov 2020, 3 months.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 3 months is below that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2020
First posted
Sep 16, 2020
StartActual
Aug 5, 2020
Primary completionActual
Nov 26, 2020
CompletionActual
Nov 26, 2020
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04550325
Lead sponsor
Kamada, Ltd.
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Aug 5, 2020
Primary completion
Nov 26, 2020
Completion
Nov 26, 2020
Last update
Jan 5, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion